​

Evaxion Biotech (EVAX) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

EVAX Stock Rating

Evaxion Biotech stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

EVAX Price Target Upside V Benchmarks

TypeNameUpside
StockEvaxion Biotech-
SectorHealthcare Stocks 18.80%
IndustryBiotech Stocks 54.28%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.94$2.94$2.94
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2511---2
Jun, 2511---2
May, 2511---2
Apr, 2511---2
Mar, 2511---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 20, 2024H.C. WainwrightBuyBuyhold
Nov 17, 2022OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-45 $-35 $-25 $-15 $-5 $5 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.11-----
Avg Forecast$-38.67$-4.10$-7.86$2.76$0.25$3.30
High Forecast$-35.34$-1.53$-0.98$3.22$0.29$3.80
Low Forecast$-42.00$-6.67$-14.73$2.30$0.21$2.80
Surprise %-79.03%-----

Revenue Forecast

$0 $20M $40M $60M $80M $100M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$73.11K-----
Avg Forecast$73.00K$4.48M$7.92M$26.55M$26.67M$85.94M
High Forecast$81.53K$5.71M$8.85M$29.65M$29.78M$95.99M
Low Forecast$64.47K$3.24M$7.00M$23.45M$23.55M$75.89M
Surprise %0.15%-----

Net Income Forecast

$-600M $-460M $-320M $-180M $-40M $100M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-22.16M-----
Avg Forecast$-528.49M$-56.04M$-107.38M$37.72M$3.35M$45.10M
High Forecast$-482.99M$-20.85M$-13.38M$43.94M$3.94M$51.96M
Low Forecast$-573.99M$-91.23M$-201.39M$31.50M$2.90M$38.25M
Surprise %-95.81%-----

EVAX Forecast FAQ

Is Evaxion Biotech stock a buy?

Evaxion Biotech stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Evaxion Biotech is a favorable investment for most analysts.

What is Evaxion Biotech's price target?

Evaxion Biotech's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $2.94.

How does Evaxion Biotech stock forecast compare to its benchmarks?

Evaxion Biotech's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (18.80%) and underperforming the biotech stocks industry (54.28%).

What is the breakdown of analyst ratings for Evaxion Biotech over the past three months?

  • July 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Evaxion Biotech’s EPS forecast?

Evaxion Biotech's average annual EPS forecast for its fiscal year ending in December 2024 is $-4.1, marking a -49.45% decrease from the reported $-8.11 in 2023. Estimates for the following years are $-7.86 in 2025, $2.76 in 2026, $0.25 in 2027, and $3.3 in 2028.

What is Evaxion Biotech’s revenue forecast?

Evaxion Biotech's average annual revenue forecast for its fiscal year ending in December 2024 is $4.48M, reflecting a 6028.04% increase from the reported $73.11K in 2023. The forecast for 2025 is $7.92M, followed by $26.55M for 2026, $26.67M for 2027, and $85.94M for 2028.

What is Evaxion Biotech’s net income forecast?

Evaxion Biotech's net income forecast for the fiscal year ending in December 2024 stands at $-56.038M, representing an 152.89% increase from the reported $-22.159M in 2023. Projections indicate $-107M in 2025, $37.72M in 2026, $3.35M in 2027, and $45.1M in 2028.